Literature DB >> 18757142

Comparison of antibody responses after vaccination with two inactivated rabies vaccines.

J M Minke1, J Bouvet, F Cliquet, M Wasniewski, A L Guiot, L Lemaitre, C Cariou, V Cozette, L Vergne, P M Guigal.   

Abstract

Thirty laboratory dogs were randomly assigned to two groups (A and B) of 15 dogs and subcutaneously vaccinated with a single dose of one of two commercially available monovalent inactivated rabies vaccines: RABISIN (Merial, France) (group A) and NOBIVAC Rabies (Intervet International) (group B). Rabies antibodies were measured over a period of 4 months using the fluorescent antibody virus neutralization (FAVN) test. The two vaccines performed differently in terms of magnitude and persistence of rabies antibodies titers in dogs. Two weeks after vaccination, average rabies antibody titers peaked at 2.53 IU/mL (range, 0.17-13.77 IU/mL) and 1.26 IU/mL (range, 0.50-4.56 IU/mL) in groups A and B dogs, respectively. The average FAVN antibody titres against rabies on D28, D56, D84, D112 and D120 were significantly higher in group A than in group B. Although all dogs from group B serologically responded to vaccination, the proportion of dogs with antibody titres >or=0.5 IU/mL dropped significantly after D28 and was statistically significantly lower on D56, D84 and D112 compared to group A dogs. In conclusion, in the context of international trade, the choice of the vaccine and the timing of blood tests are critical factors in achieving successful serological test results after rabies vaccination. RABISIN induces high and sustained antibody titres against rabies, increasing the flexibility for the time of blood sampling after primo-vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757142     DOI: 10.1016/j.vetmic.2008.06.024

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  18 in total

1.  Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs.

Authors:  James P McGettigan; Frederic David; Monica Dias Figueiredo; Jules Minke; Teshome Mebatsion; Matthias J Schnell
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

2.  One Health approach to cost-effective rabies control in India.

Authors:  Meagan C Fitzpatrick; Hiral A Shah; Abhishek Pandey; Alyssa M Bilinski; Manish Kakkar; Andrew D Clark; Jeffrey P Townsend; Syed Shahid Abbas; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-20       Impact factor: 11.205

3.  Risks related to a possible reduction of the waiting period for dogs after rabies antibody titration to 30 days compared with 90 days of the current EU legislative regime.

Authors:  Julio Alvarez; Søren Saxmose Nielsen; Emmanuelle Robardet; Arjan Stegeman; Steven Van Gucht; Vlad Vuta; Sotiria-Eleni Antoniou; Inma Aznar; Alexandra Papanikolaou; Helen Clare Roberts
Journal:  EFSA J       Date:  2022-06-02

4.  Immune Response After Rabies Vaccination in Owned Free-Roaming Domestic Dogs in Flores Island, Indonesia.

Authors:  Ewaldus Wera; Charlotte Warembourg; Petrus M Bulu; Maria M Siko; Salome Dürr
Journal:  Front Vet Sci       Date:  2022-06-09

5.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

6.  Quantitative risk assessment of the introduction of rabies into Japan through the importation of dogs and cats worldwide.

Authors:  N C L Kwan; K Sugiura; Y Hosoi; A Yamada; E L Snary
Journal:  Epidemiol Infect       Date:  2017-01-18       Impact factor: 4.434

7.  Factors associated with the success of rabies vaccination of dogs in Sweden.

Authors:  Louise T Berndtsson; Ann-Kristin J Nyman; Esteban Rivera; Berndt Klingeborn
Journal:  Acta Vet Scand       Date:  2011-03-25       Impact factor: 1.695

8.  Achieving population-level immunity to rabies in free-roaming dogs in Africa and Asia.

Authors:  Michelle K Morters; Trevelyan J McKinley; Daniel L Horton; Sarah Cleaveland; Johan P Schoeman; Olivier Restif; Helen R Whay; Amelia Goddard; Anthony R Fooks; I Made Damriyasa; James L N Wood
Journal:  PLoS Negl Trop Dis       Date:  2014-11-13

9.  Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania.

Authors:  Meagan C Fitzpatrick; Katie Hampson; Sarah Cleaveland; Imam Mzimbiri; Felix Lankester; Tiziana Lembo; Lauren A Meyers; A David Paltiel; Alison P Galvani
Journal:  Ann Intern Med       Date:  2014-01-21       Impact factor: 25.391

10.  A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge.

Authors:  Xiaohui Liu; Youtian Yang; Zhaojin Sun; Jing Chen; Jun Ai; Can Dun; Zhen F Fu; Xuefeng Niu; Xiaofeng Guo
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.